---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-22-000023"
form_type: "8-K/A"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2022-07-20T23:59:59+00:00"
generated_at: "2026-06-24T11:52:40.884166+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance

## Summary
- Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.
- MS revenue $1,719M (-4% YoY); SPINRAZA $431M (-14%); Biosimilars $194M.
- FDA Priority Review for lecanemab in early Alzheimer's; decision by Jan 6, 2023; Phase 3 data expected Fall 2022.
- Positive Phase 3 for zuranolone in PPD; joint US filing for MDD and PPD expected H2 2022.
- Company raises full year 2022 financial guidance.

## SEC filing metadata
- accession: 0000875045-22-000023
- form_type: 8-K/A
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2022-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/0000875045-22-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504522000023/biib-20220720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-22-000023
- JSON: https://secwatch.observer/filing/0000875045-22-000023.json
- Plain text: https://secwatch.observer/filing/0000875045-22-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.